Area of research
Oncology · Hepatology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Hepatocellular Carcinoma Treatment and Prognosis, Colorectal Cancer Treatments and Studies, and Genetic factors in colorectal cancer.
Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient (pMMR) and deficient (dMMR) colorectal cancer (CRC): NEST clinical trial update.
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
508 Generalizability of predictive versus prognostic indicators from published transcriptomic associations with tumor response to immune checkpoint inhibition
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an observational study
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study